Posted by Michael Wonder on 09 May 2023
Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients
8 May 2023 - FDA approval means patients with heart failure can benefit from Farxiga regardless of left ventricular ejection fraction status.
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults with heart failure.
